Moreover, an interim analysis of derazantinib treatment in patients (n = 23) with advanced iCCA exhibiting FGFR2 mutations or amplifications previously treated with chemotherapy demonstrated a DCR of 73.9% (95% CI, 51.6–89.8) with an mPFS of 7.3 (3.5–16.7) months [51]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.